Form 4: 89bio CMO Sells Shares, Options in Roche Merger

89bio's Chief Medical Officer, Harry H. Mansbach, disposed of all his common stock and options following the company's acquisition by Roche Holdings, Inc. for $14.50 cash plus a CVR.

Summary

• Harry H. Mansbach, Chief Medical Officer of 89bio, Inc., reported changes in his beneficial ownership due to the merger of 89bio, Inc. with Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Roche Holdings, Inc.
• The merger was completed on October 30, 2025, following a tender offer by Roche Holdings, Inc. and Bluefin Merger Subsidiary, Inc.
• Shareholders received an offer price of $14.50 per share in cash, plus one non-tradeable Contingent Value Right (CVR) representing the right to receive up to an additional $6.00 per share upon achievement of specified milestones.
• Mansbach acquired 50,000 shares of common stock from the settlement of performance-based restricted stock units (RSUs) immediately prior to the merger.
• He then disposed of 352,656 shares of common stock as part of the merger, resulting in zero shares beneficially owned.
• All outstanding stock options held by Mansbach became fully vested and exercisable, then were cancelled and converted into cash consideration (Closing Amount minus exercise price) plus one CVR per share, or CVRs and potential milestone payments for certain out-of-the-money options, or cancelled without payment for options with exercise prices equal to or greater than $20.50.
• Mansbach disposed of all his stock options, including those with exercise prices ranging from $1.93 to $32.50, and now holds zero derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is generally positive for the reporting person and shareholders due to the successful completion of a merger, providing liquidity and potential upside via CVRs. However, the non-tradeable nature of CVRs and the cancellation of deeply out-of-the-money options introduce minor caveats.

Positives

• The merger provided a clear exit strategy and liquidity for shareholders, including the reporting person.
• Performance-based restricted stock units (RSUs) vested immediately prior to the merger, converting into common stock that was then exchanged for the merger consideration.
• All outstanding stock options became fully vested and exercisable, allowing the reporting person to realize value from them, provided their exercise price was below the total potential offer price.
• The offer included a Contingent Value Right (CVR) component, providing potential upside of up to $6.00 per share based on future milestone achievements.

Negatives

• Options with an exercise price equal to or greater than $20.50 were cancelled without any payment, meaning no value was realized from those specific options.
• The CVRs are non-tradeable, limiting immediate liquidity for the contingent portion of the consideration.
• The reporting person no longer holds any equity in 89bio, Inc. post-merger.

Risks

• The value of the Contingent Value Rights (CVRs) is dependent on the achievement of specified milestones, which may not occur, potentially reducing the total realized value per share from the maximum $20.50.
• The CVRs are non-tradeable, meaning there is no market for them, and their value cannot be realized until milestones are met or not met.

Future Outlook

The filing details the completion of the merger, indicating that 89bio, Inc. is now a wholly owned subsidiary of Roche Holdings, Inc. The future outlook for former 89bio shareholders who received CVRs depends on the achievement of specified milestones by the acquired company's assets.

Industry Context

This transaction represents a strategic acquisition by a major pharmaceutical company (Roche) of a biotechnology firm (89bio), a common trend in the life sciences sector where larger players seek to acquire innovative pipelines or technologies. The use of Contingent Value Rights (CVRs) is also a frequent mechanism in biotech M&A, allowing acquirers to mitigate risk while providing potential upside to sellers based on clinical or regulatory success.

Comparison to Industry Standards

• The offer structure, combining an upfront cash payment with a non-tradeable CVR, is a common approach in biotech acquisitions, similar to deals like Sanofi's acquisition of Kadmon Holdings or Bristol Myers Squibb's acquisition of MyoKardia.
• The total potential value of $20.50 per share (including CVR) would need to be compared to 89bio's pre-announcement trading price and analyst price targets to assess its premium relative to industry benchmarks for similar-stage biotech companies.
• The cancellation of out-of-the-money options (especially those with exercise prices equal to or greater than $20.50) is standard practice in M&A, ensuring that only in-the-money or near-the-money options receive consideration.

Stakeholder Impact

• Shareholders: Received cash and CVRs for their shares, providing liquidity and potential future upside.
• Employees (including reporting person): Equity holdings were converted into merger consideration, providing financial benefit. The merger likely impacts employment status and organizational structure, though not detailed in this filing.
• Roche Holdings, Inc.: Acquired 89bio, Inc., expanding its pipeline or market presence.

Next Steps

• Achievement of specified milestones for the Contingent Value Rights (CVRs) to trigger additional payments.
• Integration of 89bio, Inc. into Roche Holdings, Inc. as a wholly owned subsidiary.

Key Dates

Keywords

89bio, ETNB, Roche Holdings, Merger, Acquisition, Form 4, Insider Transaction, Stock Options, Restricted Stock Units, Contingent Value Rights, Biotechnology, Pharmaceuticals